TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07633288: A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (S

Sponsor: SynAct Pharma Aps · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,880,400

Rescue Site Savings

+$3,234,000

Unlock Full NCT07633288 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07633288 Rescue Dossier →